The present paper summarizes by systematic review and meta-analysis approach the current evidence regarding the effectiveness of anti-tumor necrosis factor α (anti-TNFα) treatments in childhood autoimmune chronic uveitis (ACU), refractory to previous disease-modifying antirheumatic drugs (DMARDs). Although randomized controlled trials are needed, the available evidence suggests that Iinfliximab and Adalimumab provide proven similar benefits in the treatment of childhood ACU, and they are both superior to ETA.
Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: A systematic review and meta-analysis approach of individual drugs / Simonini, Gabriele; Druce, Katie; Cimaz, Rolando; Macfarlane, Gary J.; Jones, Gareth T.. - In: ARTHRITIS CARE & RESEARCH. - ISSN 2151-464X. - STAMPA. - 66:(2014), pp. 1073-1084. [10.1002/acr.22214]
Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: A systematic review and meta-analysis approach of individual drugs
SIMONINI, GABRIELE;CIMAZ, ROLANDO;
2014
Abstract
The present paper summarizes by systematic review and meta-analysis approach the current evidence regarding the effectiveness of anti-tumor necrosis factor α (anti-TNFα) treatments in childhood autoimmune chronic uveitis (ACU), refractory to previous disease-modifying antirheumatic drugs (DMARDs). Although randomized controlled trials are needed, the available evidence suggests that Iinfliximab and Adalimumab provide proven similar benefits in the treatment of childhood ACU, and they are both superior to ETA.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2014 Arhritis Care & Research.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
495.11 kB
Formato
Adobe PDF
|
495.11 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
